Houston Methodist · Mar 2025
Describes Houston Methodist’s leading role in the SAVE Fistulas randomized controlled trial and notes the trial is evaluating VenoStent’s SelfWrap bioabsorbable wrap for CKD patients needing AV fistulas.
Company research
Public company, workplace, funding, and market signals
Overview
VenoStent is a Houston-based, clinical-stage therapeutic medical device company developing SelfWrap, a bioabsorbable perivascular wrap used during arteriovenous fistula creation to improve maturation and patency for dialysis access.
Primary product
SelfWrap bioabsorbable perivascular wrap
Founded
2017
Headquarters
Houston, Texas, United States
Team size
11-50
Work style
Onsite
Industry
Medical Device
Sub-industry
Vascular surgery / tissue engineering
Offices
Houston, Texas, United States
Nashville, Tennessee, United States
Business model
clinical-stage medical device development
Funding
Stage
Series A
Total raised
$30.1M
Latest round
Series A · Jun 2024
Latest amount
$20M
People & investors
Leadership
President and CEO
COO and Co-founder
VP of Clinical Affairs
VP of Research and Engineering
VP of Quality Assurance
Chief Compliance Officer
Investors
Activated Capital
Alumni Ventures
Baylor Angel Network / Affinity Fund
C3 Ventures
Cougar Ventures
Cowtown Angels
Creative Ventures
Good Growth Capital
Health Wildcatters
IAG Capital Partners
LaunchTN
National Institutes of Health
National Science Foundation
Norwest Venture Partners
Olima Ventures
SP Investment Fund
Texas HALO Fund
TMC Venture Fund
Y Combinator
Work & culture
Cross-disciplinary, R&D-heavy medtech culture focused on translational vascular-device development, clinical trials, and regulatory progress.
Work style
Onsite
Compensation
No public salary bands or compensation details were found in the sources reviewed; public hiring activity is visible, but compensation is not disclosed.
Product & market
Pricing
Not publicly disclosed; investigational device not yet commercially sold.
Differentiators
- —Bioabsorbable wrap that is absorbed by the body
- —Designed to improve AVF maturation and patency
- —3D-printed and tuned for conforming fit
- —Clinical-stage with FDA Breakthrough Device Designation and IDE trial
Technology
bioabsorbable polymers
shape memory polymers
3D printing
biomaterials
tissue engineering
medical 3D printing
vascular surgery device design
Customers
Chronic kidney disease patients requiring hemodialysis
vascular surgeons
dialysis access clinical trial sites and hospitals
Competitors
Laminate Medical Technologies (VasQ External Vascular Support)
Scale & contact
Estimated revenue
$1M-$10M
Estimated monthly visits
1.5K
Traffic estimate as of Jun 2026
Latest news
PRNewswire · Jun 2024
Company closed its Series A at $20M, adding $4M from Norwest Venture Partners, and said the NIH awarded a $3.6M SBIR Phase II grant to support its U.S. clinical trial.
MassDevice · Jun 2024
Covers the same financing and highlights that Good Growth Capital and IAG Capital Partners co-led the round, with Norwest joining via the $4M add-on.
Yahoo Finance / AccessWire · Jul 2023
Reports the company’s $16M Series A initial close and FDA IDE approval to begin the SAVE-FistulaS U.S. trial.
AP News · May 2022
Announces FDA Breakthrough Device Designation for SelfWrap and explains the regulatory significance for the investigational device.
Jobs and careers at VenoStent
0 jobs at VenoStent
No open positions
Check back later for new openings